Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Pompe Disease Treatment Market

ID: MRFR/HC/11343-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026

US Pompe Disease Treatment Market Research Report: By Treatment Type (Enzyme Replacement Therapy, Gene Therapy, Chaperone Therapy, Substrate Reduction Therapy), By Disease Severity (Infantile Pompe Disease, Late-Onset Pompe Disease, Classical Pompe Disease), By Route of Administration (Intravenous, Subcutaneous, Oral) and By Patient Age Group (Pediatric, Adult) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Pompe Disease Treatment Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Industrial Automation & Equipment, BY Type (USD Million)
  49.     4.1.1 Enzyme Replacement Therapy
  50.     4.1.2 Gene Therapy
  51.     4.1.3 Chaperone Therapy
  52.     4.1.4 Substrate Reduction Therapy
  53.   4.2 Industrial Automation & Equipment, BY Disease Severity (USD Million)
  54.     4.2.1 Infantile Pompe Disease
  55.     4.2.2 Late-Onset Pompe Disease
  56.     4.2.3 Classical Pompe Disease
  57.   4.3 Industrial Automation & Equipment, BY Route of Administration (USD Million)
  58.     4.3.1 Intravenous
  59.     4.3.2 Subcutaneous
  60.     4.3.3 Oral
  61.   4.4 Industrial Automation & Equipment, BY Patient Age Group (USD Million)
  62.     4.4.1 Pediatric
  63.     4.4.2 Adult
  64. 5 SECTION V: COMPETITIVE ANALYSIS
  65.   5.1 Competitive Landscape
  66.     5.1.1 Overview
  67.     5.1.2 Competitive Analysis
  68.     5.1.3 Market share Analysis
  69.     5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  70.     5.1.5 Competitive Benchmarking
  71.     5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  72.     5.1.7 Key developments and growth strategies
  73.       5.1.7.1 New Product Launch/Service Deployment
  74.       5.1.7.2 Merger & Acquisitions
  75.       5.1.7.3 Joint Ventures
  76.     5.1.8 Major Players Financial Matrix
  77.       5.1.8.1 Sales and Operating Income
  78.       5.1.8.2 Major Players R&D Expenditure. 2023
  79.   5.2 Company Profiles
  80.     5.2.1 Sanofi (FR)
  81.       5.2.1.1 Financial Overview
  82.       5.2.1.2 Products Offered
  83.       5.2.1.3 Key Developments
  84.       5.2.1.4 SWOT Analysis
  85.       5.2.1.5 Key Strategies
  86.     5.2.2 Genzyme (US)
  87.       5.2.2.1 Financial Overview
  88.       5.2.2.2 Products Offered
  89.       5.2.2.3 Key Developments
  90.       5.2.2.4 SWOT Analysis
  91.       5.2.2.5 Key Strategies
  92.     5.2.3 Amicus Therapeutics (US)
  93.       5.2.3.1 Financial Overview
  94.       5.2.3.2 Products Offered
  95.       5.2.3.3 Key Developments
  96.       5.2.3.4 SWOT Analysis
  97.       5.2.3.5 Key Strategies
  98.     5.2.4 Pfizer (US)
  99.       5.2.4.1 Financial Overview
  100.       5.2.4.2 Products Offered
  101.       5.2.4.3 Key Developments
  102.       5.2.4.4 SWOT Analysis
  103.       5.2.4.5 Key Strategies
  104.     5.2.5 Boehringer Ingelheim (DE)
  105.       5.2.5.1 Financial Overview
  106.       5.2.5.2 Products Offered
  107.       5.2.5.3 Key Developments
  108.       5.2.5.4 SWOT Analysis
  109.       5.2.5.5 Key Strategies
  110.     5.2.6 Roche (CH)
  111.       5.2.6.1 Financial Overview
  112.       5.2.6.2 Products Offered
  113.       5.2.6.3 Key Developments
  114.       5.2.6.4 SWOT Analysis
  115.       5.2.6.5 Key Strategies
  116.     5.2.7 AstraZeneca (GB)
  117.       5.2.7.1 Financial Overview
  118.       5.2.7.2 Products Offered
  119.       5.2.7.3 Key Developments
  120.       5.2.7.4 SWOT Analysis
  121.       5.2.7.5 Key Strategies
  122.     5.2.8 Eisai (JP)
  123.       5.2.8.1 Financial Overview
  124.       5.2.8.2 Products Offered
  125.       5.2.8.3 Key Developments
  126.       5.2.8.4 SWOT Analysis
  127.       5.2.8.5 Key Strategies
  128.   5.3 Appendix
  129.     5.3.1 References
  130.     5.3.2 Related Reports
  131. 6 LIST OF FIGURES
  132.   6.1 MARKET SYNOPSIS
  133.   6.2 US MARKET ANALYSIS BY TYPE
  134.   6.3 US MARKET ANALYSIS BY DISEASE SEVERITY
  135.   6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  136.   6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
  137.   6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
  138.   6.7 RESEARCH PROCESS OF MRFR
  139.   6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
  140.   6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
  141.   6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
  142.   6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
  143.   6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
  144.   6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
  145.   6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE SEVERITY, 2024 (% SHARE)
  146.   6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE SEVERITY, 2024 TO 2035 (USD Million)
  147.   6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  148.   6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
  149.   6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PATIENT AGE GROUP, 2024 (% SHARE)
  150.   6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
  151.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  152. 7 LIST OF TABLES
  153.   7.1 LIST OF ASSUMPTIONS
  154.     7.1.1
  155.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  156.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  157.     7.2.2 BY DISEASE SEVERITY, 2025-2035 (USD Million)
  158.     7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  159.     7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  160.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  161.     7.3.1
  162.   7.4 ACQUISITION/PARTNERSHIP
  163.     7.4.1

US Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Type (USD Million, 2025-2035)

  • Enzyme Replacement Therapy
  • Gene Therapy
  • Chaperone Therapy
  • Substrate Reduction Therapy

Industrial Automation & Equipment By Disease Severity (USD Million, 2025-2035)

  • Infantile Pompe Disease
  • Late-Onset Pompe Disease
  • Classical Pompe Disease

Industrial Automation & Equipment By Route of Administration (USD Million, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Oral

Industrial Automation & Equipment By Patient Age Group (USD Million, 2025-2035)

  • Pediatric
  • Adult

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓